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the analysis. The model’s effectiveness outcome is deﬁned as patients who are success-
fully treated and are alive. Cost-effectiveness is measured as total costs per patient 
with respect to effectiveness for each medication arm. In addition, sensitivity analyses 
were performed to identify cost-effectiveness for different clinical and economic 
assumptions. RESULTS: The analysis shows that 60% of MICA patients were suc-
cessfully treated and survived at the end of study compared to 58% of CASPO 
patients. Furthermore, the costs of a MICA treatment (a37,212) are below the costs 
of a CASPO treatment (a37,720). Therefore, the cost-effectiveness ratio is lower for 
MICA (a62,377) than for CASPO (a65,565). This result also holds for all but one of 
the sensitivity analyses. However, probabilistic sensitivity and subgroup analyses show 
that differences cannot be considered statistically signiﬁcant due to large variance. For 
European patients only, who can be assumed to be a more homogenous group and a 
better approximation of German patients, cost-effectiveness ratio for MICA is 59,406 
a compared to a68,217 for CASPO, the difference being statistically signiﬁcant. 
CONCLUSIONS: This study analyzes the cost-effectiveness of MICA as compared to 
CASPO for the treatment of systemic candida infections in Germany. Both lower costs 
and higher effectiveness of MICA render MICA as more cost-effective than CASPO.
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OBJECTIVES: To establish a cost-effective intravenous antibiotic therapy in the treat-
ment of Infective Endocarditis and Bacteremia. METHODS: A cost-effectiveness study 
was performed considering the expenses and use of resources of Mexican Public Health 
Institutions. The study was based on a decision tree with Bayesian approach deﬁning 
three different health states: clinical success (within short or long hospital stay frame), 
therapeutic failure, and death. The alternatives compared were: a) i.v. Vancomycin 
(VAN) as a ﬁrst-line antibiotic therapy followed by a second-line antibiotic therapy 
in therapeutic failure, or b) i.v. Daptomycin (DAP) as a ﬁrst-line or second-line anti-
biotic therapy. The most recent published data concerning efﬁcacies, length of hospital 
stay and adverse events were included in the study. Results were evaluated with 
incremental analysis and one-way sensitivity analysis of most uncertain variables. 
RESULTS: The use of i.v. Daptomycin as ﬁrst-line antibiotic therapy represents savings 
of US$4,619.00 per patient reaching clinical success (CS) when compared to the use 
of i.v. Vancomycin as ﬁrst-line antibiotic therapy (DAP-VAN: US$21,168.00/CS; 
VAN-2nd line antibiotic: US$25,787.00/CS). A greater proportion of patients are more 
likely to attain clinical success when DAP is used as ﬁrst-line antibiotic therapy (DAP-
VAN: 62%; VAN-2nd line antibiotic: 54%) due to a less frequent development of 
adverse events compared to the use of VAN. The sensitivity analysis varying clinical 
success rates of every evaluated alternative demonstrated the robustness of the base 
study. CONCLUSIONS: Daptomycin is the most cost-effective alternative in the treat-
ment of Infective Endocarditis and Bacteremia when used as ﬁrst-line antibiotic therapy 
since it decreases hospital expenses due to a reduced hospital stay and results in a 
greater proportion of patients reaching clinical success. The use of Vancomycin in 
long term treatments is associated with a higher frequency of adverse events which 
can cause treatment interruption resulting in therapeutic failure.
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OBJECTIVES: To estimate the impact of the use of more detailed direct medical costs 
for the economic evaluations (EEs) of universal vaccinations against rotavirus and 
varicella in Brazil on the incremental cost-effectiveness ratios (ICERs). METHODS: 
Previous published EEs were used as basis and new direct medical costs estimates for 
rotavirus and varicella were developed, with the inclusion of speciﬁc costs of the private 
health care system (HCS) for the two diseases, inclusion of public participation for 
dispensing drugs in the case of rotavirus and inclusion of drugs costs in the public HCS 
in the case of varicella. Cost estimate methods consisted of gross-costing and micro-
costing. Data were obtained from national regulatory agency database (ANS), house-
hold survey (PNAD), private (CBHPM, TUNEP) and public (Ministry of Health) 
reference lists. Direct medical costs were then applied to the previous models, preserv-
ing non-medical direct and indirect costs, all costs in 2004 Reals. ICERs were recalcu-
lated and compared to the original calculations, from the HCS and societal perspective. 
Univariate sensitivity analysis was performed to each cost item and discount rate to 
analyse individual impact on ICER. RESULTS: From the societal perspective, there 
was an estimated disease total cost increase of 16% for rotavirus and 11% for varicella, 
as well as increase of savings with the vaccination of 18% and 16%, respectively. 
ICERs were reduced by 20% for rotavirus (to a292/LYS) and 4% for varicella (to 
a4098/LYS), still below the threshold (3xGDP per capita). Sensitivity analysis indicated 
that EEs of vaccination against rotavirus and varicella were more sensitive to the vac-
cination program cost estimates, especially the vaccine price. CONCLUSIONS: 
Although the more detailed cost estimates reduced the ICERs, the level of cost-effective-
ness of the two vaccination programs remained the same. Sensitivity analysis pointed 
out the relevance of the vaccine cost comparatively to the direct medical costs.
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OBJECTIVES: Standard treatment for hepatitis C is peginterferon (PEG-IFN)  RBV 
with the aim of achieving a sustained-virological-response (SVR), which is widely 
considered to be a cure. Around 50% of patients infected with G1 do not achieve 
an SVR but re-treatment with PEG-IFN  RBV is successful in some, especially in 
those who achieve a complete-early-virological-response (HCV-RNA undetectable 
by week 12 [cEVR]). The objective of this analysis was to determine the cost-effective-
ness of re-treating previous G1-non-responders to PEG-IFN  RBV. METHODS: 
A published Markov-model compared three strategies: PEG-IFNA2a  RBV, for 72 
weeks (A), 48 weeks (B) or no treatment (C). Efﬁcacy data for (A) and (B) were taken 
from the REPEAT study, where a difﬁcult-to-treat population of G1-patients with 
previous non-response to PEG-IFN/RBV was investigated. Rates of cEVR were 15% 
for (A) and 9% for (B); SVR rates: 13% for (A) and 7% for (B); rates for (C) assumed 
to be zero. Patients not achieving a cEVR were assumed to discontinue treatment. 
A UK health care payor perspective was adopted. Drug and other costs were taken 
from published sources. A lifetime-horizon was chosen. Incremental-cost-effectiveness-
ratios were expressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs 
were discounted at 3.5% p.a. Sensitivity-analyses were performed. RESULTS: 
The analysis showed that an additional SVR prevented future costs and increased 
quality-adjusted-life-expectancy. Although (A) caused the highest overall drug costs, 
total costs were only £606 higher compared to (B) and £1949 compared to (C), 
reﬂecting the higher SVR rates and the substantial medical costs for patients without 
an SVR. The ICER of (A) vs. (B) was estimated at £2,012/QALY and £2,988/QALY 
for (A) vs. (C). CONCLUSIONS: Re-treatment with PEG-IFNA2a  RBV for 72 weeks 
is a highly cost-effective treatment option for patients not responding to previous 
treatment with PEG-IFN  RBV, regardless of comparator, due to reduction of 
the high medical costs associated with progressive liver disease and the associated 
QALY gains.
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OBJECTIVES: The 7-valent pneumococcal conjugate vaccine (PCV7) and 23-valent 
pneumococcal polysaccharide vaccine (PPV23) are currently recommended for child-
hood and adult vaccination respectively in the UK. A 13-valent pneumococcal conju-
gate vaccine (PCV13) is currently being reviewed by regulatory authorities for use in 
infants and young children, and a clinical development plan for adults is ongoing. 
This study assessed cost-effectiveness of PCV13 compared to the current vaccination 
strategy and to PCV7 given to children alone. METHODS: A steady state, static 
cohort model was constructed comparing PCV13 vaccination of the birth cohort and 
of 65-year old adults with the current strategy and with PCV7 in children alone. The 
model con sidered the incidence and subsequent costs of four infections: pneumococcal 
meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media 
(AOM). Vaccination was assumed to have effects on vaccinated individuals and to 
impact unvaccinated individuals as a result of herd immunity. The number of cases 
and subsequent costs that would occur were estimated in the different scenarios. Sen-
sitivity analysis considered incidence, mortality rates, vaccine efﬁcacy, serotype cover, 
costs, discount rate, uptake and herd immunity. RESULTS: The model estimated that, 
compared to the current strategy (and compared to PCV7 alone), PCV13 would reduce 
the annual incidence of bacteraemia and meningitis by 1176 (1303) cases, prevent 35 
(40) deaths, increase life years by 619 (666), increase QALYs by 694 (731) and reduce 
medical costs by £2.9m (£11.1m). Results are sensitive to vaccine effects against 
pneumonia and the disease incidence in non-vaccinated individuals. CONCLUSIONS: 
Paediatric and adult PCV13 vaccination in the UK was estimated to reduce the burden 
of pneumococcal disease and save costs compared with either the current vaccination 
strategy or a paediatric PCV7 only strategy. Final cost-effectiveness will depend on 
the emergence of herd immunity beneﬁts in the UK, impact on pneumonia, vaccine 
schedule and price.
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OBJECTIVES: To determine the cost-effectiveness of the protocol of the international          
‘Surviving Sepsis Campaign’ (SSC) for the treatment of severe sepsis in Spain after the 
implementation of a multicentre educational program compared with the conventional 
